NASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis $2.59 +0.21 (+8.82%) Closing price 04:00 PM EasternExtended Trading$2.58 -0.01 (-0.23%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Annexon Stock (NASDAQ:ANNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Annexon alerts:Sign Up Key Stats Today's Range$2.37▼$2.7450-Day Range$1.97▼$2.9652-Week Range$1.28▼$7.85Volume1.57 million shsAverage Volume1.85 million shsMarket Capitalization$284.15 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingBuy Company Overview Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Read More Annexon Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreANNX MarketRank™: Annexon scored higher than 50% of companies evaluated by MarketBeat, and ranked 561st out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnnexon has only been the subject of 2 research reports in the past 90 days.Read more about Annexon's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Annexon are expected to decrease in the coming year, from ($0.96) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Annexon's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.39% of the float of Annexon has been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Annexon has recently decreased by 0.69%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.39% of the float of Annexon has been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Annexon has recently decreased by 0.69%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.93 News SentimentAnnexon has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Annexon this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Annexon to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have sold 57.81% more of their company's stock than they have bought. Specifically, they have bought $10,123.00 in company stock and sold $15,975.00 in company stock.Percentage Held by Insiders11.87% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Annexon's insider trading history. Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address ANNX Stock News HeadlinesAnnexon, Inc. (NASDAQ:ANNX) Director Purchases $10,122.90 in StockJuly 2, 2025 | insidertrades.comAnnexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic AtrophyJuly 24, 2025 | globenewswire.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 30 at 2:00 AM | Porter & Company (Ad)Annexon: Lead GBS Therapy Stokes Near-Term PotentialJuly 14, 2025 | seekingalpha.comNoteworthy Thursday Option Activity: ANNX, SPOT, STNGJuly 12, 2025 | nasdaq.comAnnexon, Inc. (ANNX) Latest Stock News & Headlines - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comAnnexon Biosciences to Present at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comAnnexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual MeetingMay 19, 2025 | globenewswire.comSee More Headlines ANNX Stock Analysis - Frequently Asked Questions How have ANNX shares performed this year? Annexon's stock was trading at $5.13 at the start of the year. Since then, ANNX stock has decreased by 49.5% and is now trading at $2.59. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.07. When did Annexon IPO? Annexon (ANNX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO. Who are Annexon's major shareholders? Top institutional shareholders of Annexon include Mutual of America Capital Management LLC (0.98%), J. Safra Sarasin Holding AG (0.35%), Park Avenue Securities LLC (0.10%) and CWM LLC (0.02%). Insiders that own company stock include Muneer A Satter, Bain Capital Life Sciences Inv, Douglas Love, Michael Overdorf, Jennifer Lew, Ted Yednock, Dean Richard Artis, Jamie Dananberg and William H Carson. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include NVIDIA (NVDA), MercadoLibre (MELI), Advanced Micro Devices (AMD), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Energy Transfer (ET). Company Calendar Last Earnings5/12/2025Today7/30/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANNX CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees60Year FoundedN/APrice Target and Rating Average Price Target for Annexon$12.50 High Price Target$14.00 Low Price Target$11.00 Potential Upside/Downside+385.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$138.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-54.45% Return on Assets-46.56% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book0.94Miscellaneous Outstanding Shares109,710,000Free Float95,813,000Market Cap$282.50 million OptionableOptionable Beta1.30 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:ANNX) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredSomething BIG is about to hit the stock marketMost investors won’t see it coming—but Weiss Ratings says a major market event is brewing. Their system jus...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.